Article
Direct‐to‐consumer genetic testing: Perspectives on its value in healthcare
30 Oct 2015
Abstract excerpt
The direct-to-consumer genetic testing debate reached a fever pitch in November 2013 when the US Food and Drug Administration (FDA) instructed 23andMe to discontinue marketing and sale of their Personal Genome Service. In 2015, 23andMe emerged with FDA approval to market a carrier test for Bloom syndrome only, and plans to release additional reports. The dust has settled and it is time to ask: What have we...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
